CYP11A1
Cholesterol side-chain cleavage enzyme, mitochondrial
As of the edition of 20 October 2026, CYP11A1 (cholesterol side-chain cleavage enzyme, mitochondrial, UniProt P05108) has 3 drugs tested at it and 5 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P05108
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Cancer; Hormones; Urinary and reproductive; Nutrition and metabolism; Nervous system
- Registered trials of its drugs
- 32
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Opevesostat | Active | Phase 3 | none listed |
| Mitotane | Marketed | Phase 3 | none listed |
| Levoketoconazole | Marketed | Phase 3 | Ends 2028 |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Cortendo | Route B |
The other 4 companies at CYP11A1
In the product5 companies in all; 4 are not named here, and no score is.
See the 5 companies at CYP11A1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.